J. Baker

发表

The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors.

J. Baker, 2005, British journal of pharmacology.

The selectivity of β‐adrenoceptor antagonists at the human β1, β2 and β3 adrenoceptors

Jillian G. Baker, J. Baker, 2005 .

Novel selective β1-adrenoceptor antagonists for concomitant cardiovascular and respiratory disease

Shailesh N Mistry, P. Fischer, S. Gardiner, 2017, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

Comparative Docking to Distinct G Protein–Coupled Receptor Conformations Exclusively Yields Ligands with Agonist Efficacy

P. Kolb, J. Baker, Magdalena M Scharf, 2019, Molecular Pharmacology.

THEMED SECTION: IMAGING IN PHARMACOLOGY RESEARCH PAPER Influence of fluorophore and linker composition on the pharmacology of fluorescent adenosine A1 receptor ligands

L. May, S. Hill, S. Briddon, 2010 .

A Full Pharmacological Analysis of the Three Turkey β-Adrenoceptors and Comparison with the Human β-Adrenoceptors

J. Baker, 2010, PloS one.

Novel selective b1-adrenoceptor antagonists for concomitant cardiovascular and respiratory disease

Shailesh N Mistry, P. Fischer, S. Gardiner, 2017 .

β-Blockers, heart disease and COPD: current controversies and uncertainties

R. Wilcox, J. Baker, 2016, Thorax.

Agonist and Inverse Agonist Actions of β-Blockers at the Human β2-Adrenoceptor Provide Evidence for Agonist-Directed Signaling

I. Hall, S. Hill, J. Baker, 2003 .

Temporal characteristics of cAMP response element-mediated gene transcription: requirement for sustained cAMP production.

I. Hall, S. Hill, J. Baker, 2004, Molecular pharmacology.

Pharmacological characterization of CGP 12177 at the human β2‐adrenoceptor

I. Hall, S. Hill, J. Baker, 2002 .

P. Kolb, D. Schmidt, J. Baker, 2017, ACS medicinal chemistry letters.

Evidence for a Secondary State of the Human β3-Adrenoceptor

J. Baker, 2005, Molecular Pharmacology.

The selectivity of α‐adrenoceptor agonists for the human α1A, α1B, and α1D‐adrenoceptors

J. Baker, Richard G. W. Proudman, 2021, Pharmacology research & perspectives.

The pharmacological effects of the thermostabilising (m23) mutations and intra and extracellular (β36) deletions essential for crystallisation of the turkey β-adrenoceptor

C. Tate, J. Baker, Richard G. W. Proudman, 2011, Naunyn-Schmiedeberg's Archives of Pharmacology.

Gherbi, Karolina and May, Lauren T. and Baker, Jillian G. and Briddon, Stephen J. and Hill, Stephen J. (2015) Negative cooperativity across 1-adrenoceptor homodimers provides insights into the nature of the secondary low-affinity CGP 12177 1-adrenoceptor

L. May, S. Hill, S. Briddon, 2017 .

Synthesis and Characterization of High-Affinity 4,4-Difluoro-4-bora-3a,4a-diaza-s-indacene-Labeled Fluorescent Ligands for Human β-Adrenoceptors

Shailesh N Mistry, S. Hill, J. Baker, 2011, Journal of medicinal chemistry.

Influence of fluorophore and linker composition on the pharmacology of fluorescent adenosine A₁ receptor ligands

L. May, S. Hill, S. Briddon, 2010 .

Reactions of stabilized criegee intermediates from the gas‐phase reactions of O3 with selected alkenes

S. M. Aschmann, J. Arey, R. Atkinson, 2002 .

Formation and reaction of hydroxycarbonyls from the reaction of OH radicals with 1,3-butadiene and isoprene.

J. Arey, R. Atkinson, J. Baker, 2005, Environmental science & technology.

Rate constants for the reactions of OH radicals with a series of 1,4-hydroxyketones

J. Arey, R. Atkinson, J. Baker, 2005 .

The selectivity of b -adrenoceptor antagonists at the human b 1, b 2 and b 3 adrenoceptors

J. Baker, 2005 .

Agonist and Inverse Agonist Actions of (cid:1) -Blockers at the Human (cid:1) 2 -Adrenoceptor Provide Evidence for Agonist-Directed Signaling

S. Hill, J. Baker, Ian P. Hall, 2003 .

Carvedilol blocks neural regulation of breast cancer progression in vivo and is associated with reduced breast cancer mortality in patients.

David M. Shackleford, E. Sloan, B. K. Andreassen, 2021, European journal of cancer.

Agonist actions of "beta-blockers" provide evidence for two agonist activation sites or conformations of the human beta1-adrenoceptor.

I. Hall, S. Hill, J. Baker, 2003, Molecular pharmacology.

Site of Action of β-Ligands at the Human β1-Adrenoceptor

J. Baker, 2005, Journal of Pharmacology and Experimental Therapeutics.

Agonist and inverse agonist actions of beta-blockers at the human beta 2-adrenoceptor provide evidence for agonist-directed signaling.

I. Hall, S. Hill, J. Baker, 2003, Molecular pharmacology.

The ups and downs of Gs‐ to Gi‐protein switching

S. Hill, J. Baker, 2003, British journal of pharmacology.

Fragment evolution for GPCRs: the role of secondary binding sites in optimization.

Ádám A. Kelemen, P. Kolb, G. Keserű, 2021, Chemical communications.

Pharmacology and direct visualisation of BODIPY‐TMR‐CGP: a long‐acting fluorescent β2‐adrenoceptor agonist

I. Hall, S. Hill, J. Baker, 2003, British journal of pharmacology.

Identification of Key Residues in Transmembrane 4 Responsible for the Secondary, Low-Affinity Conformation of the Human β1-Adrenoceptor

S. Hill, J. Baker, Richard G. W. Proudman, 2014, Molecular Pharmacology.

The signaling and selectivity of α‐adrenoceptor agonists for the human α2A, α2B and α2C‐adrenoceptors and comparison with human α1 and β‐adrenoceptors

J. Baker, Richard G. W. Proudman, J. Akinaga, 2022, Pharmacology research & perspectives.

The affinity and selectivity of α‐adrenoceptor antagonists, antidepressants and antipsychotics for the human α2A, α2B, and α2C‐adrenoceptors and comparison with human α1 and β‐adrenoceptors

J. Baker, Richard G. W. Proudman, J. Akinaga, 2022, Pharmacology research & perspectives.

The Isoleucine at Position 118 in Transmembrane 2 Is Responsible for the Selectivity of Xamoterol, Nebivolol, and ICI89406 for the Human β1-Adrenoceptor

Victor Jun Yu Lim, P. Kolb, J. Baker, 2022, Molecular Pharmacology.

Rate Constants for the Gas-Phase Reactions of OH Radicals with a Series of Hydroxyaldehydes at 296 ± 2 K

J. Arey, R. Atkinson, J. Baker, 2004 .

Kinetics of the Gas-Phase Reactions of OH Radicals, NO3 Radicals and O3 with Three C7-Carbonyls Formed From The Atmospheric Reactions of Myrcene, Ocimene and Terpinolene

J. Arey, R. Atkinson, J. Baker, 2004 .

Synthesis and in Vitro and in Vivo Characterization of Highly β1-Selective β-Adrenoceptor Partial Agonists

Shailesh N Mistry, P. Fischer, S. Gardiner, 2013, Journal of medicinal chemistry.

The structural basis for agonist and partial agonist action on a β1-adrenergic receptor

Christopher G. Tate, A. Leslie, C. Tate, 2010, Nature.

Structure of a β1-adrenergic G-protein-coupled receptor

Gebhard F. X. Schertler, Christopher G. Tate, Andrew G. W. Leslie, 2008, Nature.

Impact of Polymorphic Variants on the Molecular Pharmacology of the Two-Agonist Conformations of the Human β1-Adrenoceptor

S. Hill, J. Baker, Richard G. W. Proudman, 2013, PloS one.

Predicting in vivo cardiovascular properties of β-blockers from cellular assays: a quantitative comparison of cellular and cardiovascular pharmacological responses

S. Gardiner, S. Hill, J. Baker, 2011, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

The selectivity of β‐adrenoceptor agonists at human β1‐, β2‐ and β3‐adrenoceptors

J. Baker, Jillian G Baker, 2010, British journal of pharmacology.

Using Esterase Selectivity to Determine the In Vivo Duration of Systemic Availability and Abolish Systemic Side Effects of Topical β-Blockers.

P. Fischer, S. Gardiner, S. Hill, 2020, ACS pharmacology & translational science.

Reporter-gene systems for the study of G-protein-coupled receptors.

S. Rees, S. Hill, S Rees, 2001, Current opinion in pharmacology.

Evolution of β-blockers: from anti-anginal drugs to ligand-directed signalling

S. Hill, R. Summers, Jillian G. Baker, 2011, Trends in pharmacological sciences.

Influence of agonist efficacy and receptor phosphorylation on antagonist affinity measurements: differences between second messenger and reporter gene responses.

I. Hall, S. Hill, J. Baker, 2003, Molecular pharmacology.

The affinity and selectivity of α‐adrenoceptor antagonists, antidepressants, and antipsychotics for the human α1A, α1B, and α1D‐adrenoceptors

J. Baker, A. Pupo, Richard G. W. Proudman, 2020, Pharmacology research & perspectives.

Rational design, synthesis, and pharmacological evaluation of a cohort of novel beta-adrenergic receptors ligands enables an assessment of structure-activity relationships.

U. Cavallaro, J. Baker, A. Papakyriakou, 2022, European journal of medicinal chemistry.

Adrenoceptors in GtoPdb v.2023.1

R. Graham, D. Bylund, K. Minneman, 2023, IUPHAR/BPS Guide to Pharmacology CITE.

Multiple GPCR conformations and signalling pathways: implications for antagonist affinity estimates

S. Hill, J. Baker, S. Hill, 2007, Trends in pharmacological sciences.

Pharmacological Analysis and Structure Determination of 7-Methylcyanopindolol–Bound β1-Adrenergic Receptor

Jillian Baker, Christopher G Tate, Miles Congreve, 2015, Molecular Pharmacology.

Salmeterol’s Extreme β2 Selectivity Is Due to Residues in Both Extracellular Loops and Transmembrane Domains

S. Hill, J. Baker, Richard G. W. Proudman, 2015, Molecular Pharmacology.

Pharmacological characterization of CGP 12177 at the human beta(2)-adrenoceptor.

I. Hall, S. Hill, J. Baker, 2002, British Journal of Pharmacology.

Antagonist affinity measurements at the Gi-coupled human histamine H3 receptor expressed in CHO cells

J. Baker, 2008, BMC pharmacology.

A study of antagonist affinities for the human histamine H2 receptor

J. Baker, 2008, British journal of pharmacology.

Negative cooperativity across β1-adrenoceptor homodimers provides insights into the nature of the secondary low-affinity CGP 12177 β1-adrenoceptor binding conformation

L. May, S. Hill, S. Briddon, 2015, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

Response to the letter Re: Carvedilol blocks neural regulation of breast cancer progression in vivo and is associated with reduced breast cancer mortality in patients.

E. Sloan, E. Botteri, J. Baker, 2021, European journal of cancer.

Role of Key Transmembrane Residues in Agonist and Antagonist Actions at the Two Conformations of the Human β1-Adrenoceptor

Peter M Fischer, P. Fischer, S. Hill, 2008, Molecular Pharmacology.

Pharmacological and SAR analysis of the LINS01 compounds at the human histamine H1, H2, and H3 receptors

J. Baker, M. Corrêa, G. A. Fernandes, 2018, Chemical biology & drug design.

A Comparison of the Antagonist Affinities for the Gi- and Gs-Coupled States of the Human Adenosine A1-Receptor

S. Hill, J. Baker, 2007, Journal of Pharmacology and Experimental Therapeutics.

Agonist Actions of “β-Blockers” Provide Evidence for Two Agonist Activation Sites or Conformations of the Human β1-Adrenoceptor

I. Hall, S. Hill, Jillian G. Baker, 2003 .

New fluorescent adenosine A1-receptor agonists that allow quantification of ligand-receptor interactions in microdomains of single living cells.

S. Hill, S. Briddon, Y. Cordeaux, 2007, Journal of medicinal chemistry.

Case for continuing community NIV and CPAP during the COVID-19 epidemic

J. Baker, M. Sovani, 2020, Thorax.

Structure-Based Discovery of Novel Ligands for the Orexin 2 Receptor.

P. Kolb, D. Rosenbaum, J. Baker, 2020, Journal of medicinal chemistry.

Identification of Key Residues in Transmembrane 4 Responsible for the Secondary, Low-Affinity Conformation of the Human β1-Adrenoceptor

S. Hill, J. Baker, Richard G. W. Proudman, 2014, Molecular Pharmacology.

Negative cooperativity across β1-adrenoceptor homodimers provides insights into the nature of the secondary low-affinity CGP 12177 β1-adrenoceptor binding conformation

S. Briddon, Stephen J. Hill, J. Baker, 2015, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

Evolution of β-blockers: from anti-anginal drugs to ligand-directed signalling

R. Summers, J. Baker, S. Hill, 2011, Trends in pharmacological sciences.

Pharmacological Analysis and Structure Determination of 7-Methylcyanopindolol–Bound β1-Adrenergic Receptor

A. Leslie, Tomomi Sato, M. Congreve, 2015, Molecular Pharmacology.